Drug Trial Radar · NCT02849457
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Last checked: Nov 19, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Dec 2016
Primary completion
Apr 26, 2023
Study completion May 5, 2023
Sponsor
- Lead sponsor
- Martina BebinAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Jul 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 1 day, up to 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study design is a Phase IIb prospective multi-center, randomized, placebo-controlled, double-blind clinical trial. The goal will be to enroll 80 infants with Tuberous Sclerosis Complex who are less than 6 months of age prior to the onset of their first seizure
Conditions
- Tuberous Sclerosis Complex
Interventions
Early VigabatrinDrug
Subjects randomized to vigabatrin will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
Delayed Vigabatrin (Placebo)Drug
Subjects randomized to placebo will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study and continue to be followed until 36 months of age.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cognitive Assessment Scores and Developmental ImpactTime frame: 24 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California, Los Angeles
Los Angeles, California
Stanford University
Palo Alto, California
Children's National Medical Center
Washington D.C., District of Columbia
Boston Children's Hospital
Boston, Massachusetts
Beaumont Children's Hospital
Royal Oak, Michigan
Minnesota Epilepsy Group, PA
Saint Paul, Minnesota
Washington University in St. Louis
St Louis, Missouri
Duke University
Durham, North Carolina
Cincinnati's Children Hospital Medical Center
Cincinnati, Ohio
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
University of Texas Health Science Center at Houston
Houston, Texas
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.